Center-Authored Papers

Filters: Author is Mayer, Kenneth H  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
Eshleman SH, Wilson EA, Zhang XC, Ou S-S, Piwowar-Manning E, Eron JJ, McCauley M, Gamble T, Gallant JE, Hosseinipour MC et al..  2017.  Virologic outcomes in early antiretroviral treatment: HPTN 052.. HIV clinical trials. :1-10. Abstract
U
Fogel JM, Wang L, Parsons TL, Ou S-S, Piwowar-Manning E, Chen Y, Mudhune VO, Hosseinipour MC, Kumwenda J, Hakim JG et al..  2013.  Undisclosed antiretroviral drug use in a multi-national clinical trial (HPTN 052).. The Journal of infectious diseases. 208(10):1624-8. Abstract
T
Gollub EL, Morrow KM, Mayer KH, Koblin BA, Peterside PB, Husnik MJ, Metzger DS.  2010.  Three city feasibility study of a body empowerment and HIV prevention intervention among women with drug use histories: Women FIT.. Journal of women's health (2002). 19(9):1705-13. Abstract
S
Gray GE, Mayer KH, Elizaga ML, Bekker L-G, Allen M, Morris L, Montefiori D, De Rosa SC, Sato A, Gu N et al..  2016.  Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.. Clinical and vaccine immunology : CVI. 23(6):496-506. Abstract
Koblin BA, Mayer KH, Noonan E, Wang C-Y, Marmor M, Sanchez J, Brown SJ, Robertson MN, Buchbinder SP.  2012.  Sexual risk behaviors, circumcision status and pre-existing immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: Step Study.. Journal of acquired immune deficiency syndromes (1999). Abstract
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico RK, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH et al..  2017.  Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.. Annals of internal medicine. :1-10. Abstract
Fuchs JD, Bart P-A, Frahm N, Morgan C, Gilbert PB, Kochar N, De Rosa SC, Tomaras GD, Wagner TM, Baden LR et al..  2015.  Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.. Journal of AIDS & clinical research. 6(5) Abstract
P
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JHS et al..  2011.  Prevention of HIV-1 infection with early antiretroviral therapy.. The New England journal of medicine. 365(6):493-505. Abstract
Maclachlan E, Mayer KH, Barnabas R, Sanchez J, Koblin B, Duerr A.  2009.  The potential role of biomarkers in HIV preventive vaccine trials.. Journal of acquired immune deficiency syndromes (1999). 51(5):536-45. Abstract
Huang Y, Zhang L, Ledgerwood J, Grunenberg N, Bailer R, Isaacs A, Seaton K, Mayer KH, Capparelli E, Corey L et al..  2017.  Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults.. mAbs. Abstract
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico RK, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH et al..  2016.  PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305).. The Journal of infectious diseases. Abstract
N
Marzinke MA, Clarke W, Wang L, Cummings V, Liu T-Y, Piwowar-Manning E, Breaud A, Griffith S, Buchbinder S, Shoptaw S et al..  2013.  Nondisclosure of HIV Status in a Clinical Trial Setting: Antiretroviral Drug Screening Can Help Distinguish Between Newly Diagnosed and Previously Diagnosed HIV Infection.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Abstract
M
Hladik F, Burgener A, Ballweber L, Gottardo R, Vojtech L, Fourati S, Dai JY, Cameron MJ, Strobl J, Hughes SM et al..  2015.  Mucosal effects of tenofovir 1% gel.. eLife. 4 Abstract
Cranston RD, Lama JR, Richardson BA, Carballo-Diéguez A, Kunjara Na Ayudhya RP, Liu K, Patterson KB, Leu C-S, Galaska B, Jacobson CE et al..  2016.  MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Abstract
H
Brewer RA, Magnus M, Kuo I, Wang L, Liu T-Y, Mayer KH.  2014.  The high prevalence of incarceration history among black men who have sex with men in the United States: associations and implications.. American journal of public health. 104(3):448-54. Abstract
Carballo-Diéguez A, Balán IC, Brown W, Giguere R, Dolezal C, Leu C-S, Marzinke MA, Hendrix CW, Piper JM, Richardson BA et al..  2017.  High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.. PloS one. 12(7):e0181607. Abstract
F
Safren SA, Hughes JP, Mimiaga MJ, Moore AT, Friedman RK, Srithanaviboonchai K, Limbada M, Williamson BD, Elharrar V, Cummings V et al..  2016.  Frequency and predictors of estimated HIV transmissions and bacterial STI acquisition among HIV-positive patients in HIV care across three continents.. Journal of the International AIDS Society. 19(1):21096. Abstract
E
Brewer RA, Magnus M, Kuo I, Wang L, Liu T-Y, Mayer KH.  2013.  Exploring the relationship between incarceration and HIV among Black men who have sex with men in the United States.. Journal of acquired immune deficiency syndromes (1999). Abstract
Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou S-S, Anderson M, McCauley M et al..  2014.  Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.. The Lancet infectious diseases. Abstract
Mimiaga MJ, OʼCleirigh C, Biello KB, Robertson AM, Safren SA, Coates TJ, Koblin BA, Chesney MA, Donnell DJ, Stall RD et al..  2015.  The effect of psychosocial syndemic production on 4-year HIV incidence and risk behavior in a large cohort of sexually active men who have sex with men.. Journal of acquired immune deficiency syndromes (1999). 68(3):329-36. Abstract
D
Hendrix CW, Andrade A, Bumpus NN, Kashuba A, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I et al..  2015.  Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine after Directly Observed Dosing in Healthy Volunteers to establish Adherence Benchmarks (HPTN 066).. AIDS research and human retroviruses. Abstract
C
Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel DA, Nakamura YM, Godbole SV, Panchia R, Sanne I et al..  2013.  Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.. The New England journal of medicine. 369(18):1715-25. Abstract
Koblin BA, Mayer KH, Eshleman SH, Wang L, Mannheimer S, del Rio C, Shoptaw S, Magnus M, Buchbinder S, Wilton L et al..  2013.  Correlates of HIV Acquisition in a Cohort of Black Men Who Have Sex with Men in the United States: HIV Prevention Trials Network (HPTN) 061.. PloS one. 8(7):e70413. Abstract
Edwards TC, Fredericksen RJ, Crane HM, Crane PK, Kitahata MM, Mathews WC, Mayer KH, Morales LS, Mugavero MJ, Solorio R et al..  2015.  Content validity of Patient-Reported Outcomes Measurement Information System (PROMIS) items in the context of HIV clinical care.. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. Abstract
Mayer KH, Wang L, Koblin B, Mannheimer S, Magnus M, del Rio C, Buchbinder S, Wilton L, Cummings V, Watson CC et al..  2014.  Concomitant Socioeconomic, Behavioral, and Biological Factors Associated with the Disproportionate HIV Infection Burden among Black Men Who Have Sex with Men in 6 U.S. Cities.. PloS one. 9(1):e87298. Abstract